Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 4 , Pages 659-669 , August 2008

Reducing the weight of cancer: mechanistic targets for breaking the obesity–carcinogenesis link

  • Stephen D. Hursting, PhD, MPH (Professor and Chair)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 512 471 2809; Fax: +1 512 471 4661.

References 

  1. Macaulay VM. Insulin-like growth factors and cancer. British Journal of Cancer. 1992;65:311–320
  2. LeRoith D, Baserga R, Helman L, et al. Insulin-like growth factors and cancer. Annals of Internal Medicine. 1995;122:54–59
  3. Singh P, Dai B, Yallampalli U, et al. Proliferation and differentiation of a human colon cancer cell line (CaCo2) is associated with significant changes in the expression and secretion of insulin-like growth factor (IGF) IGF-II and IGF binding protein-4: role of IGF-II. Endocrinology. 1996;137:1764–1774
  4. Fenton JI, Hord NG, Lavigne JA, et al. Leptin, insulin-like growth factor-1, and insulin-like growth factor-2 are mitogens in ApcMin/+ but not Apc+/+ colonic epithelial cell lines. Cancer Epidemiological Biomarkers & Prevention. 2005;14:1646–1652
  5. Buckbinder L, Talbott R, Velasco-Miguel S, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature. 1995;377:646–649
  6. Takahashi K, Suzuki K. Association of insulin-like growth-factor-I-induced DNA synthesis with phosphorylation and nuclear exclusion of p53 in human breast cancer MCF-7 cells. International Journal of Cancer. 1993;55:453–458
  7. Le Roith D, Bondy C, Yakar S, et al. The somatomedin hypothesis: 2001. Endocrine Reviews. 2001;22:53–74
  8. Hursting SD, Switzer BR, French JE, et al. The growth hormone: insulin-like growth factor 1 axis is a mediator of diet restriction-induced inhibition of mononuclear cell leukemia in Fischer rats. Cancer Research. 1993;53:2750–2757
  9. Resnicoff M, Abraham D, Yutanawiboonchai W, et al. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Research. 1995;55:2463–2469
  10. Dunn SE, Ehrlich M, Sharp NJ, et al. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Research. 1998;58:3353–3361
  11. Hursting SD, Lavigne JA, Berrigan D, et al. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annual Review of Medicine. 2003;54:131–152
  12. Gems D, Partridge L. Insulin/IGF signalling and ageing: seeing the bigger picture. Current Opinion in Genetics & Development. 2001;11:287–292
  13. Atkinson C, Lampe JW, Tworoger SS, et al. Effects of a moderate intensity exercise intervention on estrogen metabolism in postmenopausal women. Cancer Epidemiological Biomarkers & Prevention. 2004;13:868–874
  14. Schmitz KH, Ahmed RL, Yee D. Effects of a 9-month strength training intervention on insulin, insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-1, and IGFBP-3 in 30-50-year-old women. Cancer Epidemiological Biomarkers & Prevention. 2002;11:1597–1604
  15. Colbert LH, Mai V, Perkins SN, et al. Exercise and intestinal polyp development in APCMin mice. Medicine and Science in Sports and Exercise. 2003;35:1662–1669
  16. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nature Reviews. 2004;4:579–591
  17. Yakar S, Leroith D, Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: lessons from animal models. Cytokine & Growth Factor Reviews. 2005;16:407–420
  18. Abate N. Insulin resistance and obesity. The role of fat distribution pattern. Diabetes Care. 1996;19:292–294
  19. Grimm JJ. Interaction of physical activity and diet: implications for insulin-glucose dynamics. Public Health Nutrition. 1999;2:363–368
  20. Carling D. The AMP-activated protein kinase cascade – a unifying system for energy control. Trends in Biochemical Sciences. 2004;29:18–24
  21. Hardie DG, Carling D, Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell?. Annual Review of Biochemistry. 1998;67:821–855
  22. Johnson LN, Noble ME, Owen DJ. Active and inactive protein kinases: structural basis for regulation. Cell. 1996;85:149–158
  23. Hawley SA, Boudeau J, Reid JL, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. Journal of Biology. 2003;2:28
  24. Woods A, Johnstone SR, Dickerson K, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Current Biology. 2003;13:2004–2008
  25. Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends in Biological Science. 2004;29:233–242
  26. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends in Molecular Medicine. 2005;11:353–361
  27. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 2004;6:91–99
  28. Corradetti MN, Inoki K, Bardeesy N, et al. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes & Development. 2004;18:1533–1538
  29. Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proceedings of the National Academy of Sciences of the United States of America. 2004;101:3329–3335
  30. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nature Genetics. 2005;37:19–24
  31. Tee AR, Blenis J. mTOR, translational control and human disease. Seminars in Cell & Developmental Biology. 2005;16:29–37
  32. Eng C. PTEN: one gene, many syndromes. Human Mutation. 2003;22:183–198
  33. Woods SC, Seeley RJ, Porte D, et al. Signals that regulate food intake and energy homeostasis. Science. 1998;280:1378–1383
  34. Zhang Y, Leibel R. Molecular physiology of leptin and its receptor. New England Journal of Medicine. 1998;14:17–35
  35. Jiang W, Zhu Z, Thompson H. Dietary energy restriction modulates the activity of AMP-activated protein kinase, Akt, and mammalian target of rapamycin in mammary carcinomas, mammary gland, and liver. Cancer Research. 2008;68:5492–5499
  36. Moore T, Carbijal S, Strom S, et al, Dietary energy balance modulates signaling through the Akt/mTOR pathway in multiple tissues. Cancer Prevention Research 2008; 1: 65--78.
  37. Moore T, Beltran L, Perkins SN, et al. Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating IGF-1 levels. Cancer Research. 2008;68:3680–3688
  38. Lonnqvist F, Wennlund A, Arner P. Relationship between circulating leptin and peripheral fat distribution in obese subjects. International Journal of Obesity. 1997;21:255–260
  39. Montague CT, Prins JB, Sanders L, et al. Depot- and sex-specific differences in human leptin mRNA expression: implications for the control of regional fat distribution. Diabetes. 1997;46:342–347
  40. Wilding J, Widdowson P, Williams G. Neurobiology. British Medical Bulletin. 1997;53:286–306
  41. Stattin P, Lukanova A, Biessy C, et al. Obesity and colon cancer: does leptin provide a link?. International Journal of Cancer. 2004;109:149–152
  42. Chang S, Hursting SD, Contois JH, et al. Leptin and prostate cancer. The Prostate. 2001;46:62–67
  43. Saglam K, Aydur E, Yilmaz M, et al. Leptin influences cellular differentiation and progression in prostate cancer. The Journal of Urology. 2003;169:1308–1311
  44. Bouloumie A, Drexler HC, Lafontan M, et al. Leptin, the product of Ob gene, promotes angiogenesis. Circulation Research. 1998;83:1059–1066
  45. Ostlund RE, Yang JW, Klein S, et al. Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates. The Journal of Clinical Endocrinology and Metabolism. 1996;81:3909–3913
  46. Rajala MW, Scherer PE. Minireview: the adipocyte – at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology. 2003;144:3765–3773
  47. Gonzalez RR, Cherfils S, Escobar M, et al. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). The Journal of Biological Chemistry. 2006;281:26320–26328
  48. Loffreda S, Yang SQ, Lin HZ, et al. Leptin regulates proinflammatory immune responses. The FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology. 1998;12:57–65
  49. Bråkenhielm E, Veitonmäki N, Cao R, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proceedings of the National Academy of Sciences of the United States of America. 2004;101:2476–2481
  50. Diker D, Vishne T, Maayan R, et al. Impact of gastric banding on plasma adiponectin levels. Obesity Surgery. 2006;9:1057–1061
  51. Ryan A, Nicklas B, Berma D, et al. Adiponectin levels do not change with moderate dietary induced weight loss and exercise in obese postmenopausal women. International Journal of Obesity. 2003;27:1066–1071
  52. Amitabha R, Katai N, Cleary M. Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status. International Journal of Oncology. 2007;6:1499–1509
  53. Grossmann M, Nkhata K, Mizuno N, et al. Effects of adiponectin on breast cancer cell growth and signaling. British Journal of Cancer. 2008;98:370–379
  54. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiology, Biomarkers & Prevention. 2002;11:1531–1543
  55. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867
  56. Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and aging. Science. 1996;273:59–63
  57. Tilg H, Dinarello CA, Mier JW. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunology Today. 1997;18:428–432
  58. Dinarello CA. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. The New England Journal of Medicine. 2000;343:732–734
  59. Moore KW, O'Garra A, de Waal Malefyt R, et al. Interleukin-10. Annual Review of Immunology. 1993;11:165–190
  60. Pretolani M. Interleukin-10: an anti-inflammatory cytokine with therapeutic potential. Clinical and Experimental Allergy. 1999;29:1164–1171
  61. Dobbs RJ, Charlett A, Purkiss AG, et al. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurologica Scandinavica. 1999;100:34–41
  62. Coppack SW. Pro-inflammatory cytokines and adipose tissue. The Proceedings of the Nutrition Society. 2001;60:349–356
  63. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends in Immunology. 2004;25:4–7
  64. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. The Journal of Clinical Investigation. 2003;112:1796–1808
  65. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. The Journal of Clinical Investigation. 2003;112:1821–1830
  66. Ballou SP, Lozanski FB, Hodder S, et al. Quantitative and qualitative alterations of acute-phase proteins in healthy elderly persons. Age and Ageing. 1996;25:224–230
  67. Paolisso G, Rizzo MR, Mazziotti G, et al. Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. The American Journal of Physiology. 1998;275:E294–E299
  68. Bruunsgaard H, Jensen MS, Schjerling P, et al. Exercise induces recruitment of lymphocytes with an activated phenotype and short telomeres in young and elderly humans. Life Sciences. 1999;65:2623–2633
  69. Bruunsgaard H, Skinhoj P, Pedersen AN, et al. Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clinical and Experimental Immunology. 2000;121:255–260
  70. Bruunsgaard H, Christiansen L, Pedersen AN, et al. The IL-6 -174G>C polymorphism is associated with cardiovascular diseases and mortality in 80-year-old humans. Experimental Gerontology. 2004;39:255–261
  71. Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. The Journal of Clinical Endocrinology and Metabolism. 2000;85:1151–1158
  72. Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes. 1992;41(Suppl. 2):97–101
  73. Winkler G, Salamon F, Harmos G, et al. Elevated serum tumor necrosis factor-alpha concentrations and bioactivity in Type 2 diabetics and patients with android type obesity. Diabetes Research and Clinical Practice. 1998;42:169–174
  74. Mishima Y, Kuyama A, Tada A, et al. Relationship between serum tumor necrosis factor-alpha and insulin resistance in obese men with Type 2 diabetes mellitus. Diabetes Research and Clinical Practice. 2001;52:119–123
  75. Harris TB, Savage PJ, Tell GS, et al. Carrying the burden of cardiovascular risk in old age: associations of weight and weight change with prevalent cardiovascular disease, risk factors, and health status in the Cardiovascular Health Study. The American Journal of Clinical Nutrition. 1997;66:837–844
  76. Volpato S, Guralnik JM, Ferrucci L, et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women's health and aging study. Circulation. 2001;103:947–953
  77. Erlinger TP, Platz EA, Rifai N, et al. C-reactive protein and the risk of incident colorectal cancer. JAMA : The Journal of the American Medical Association. 2004;291:585–590
  78. Lehrer S, Diamond EJ, Mamkine B, et al. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. British Journal of Urology International. 2005;95:961–962
  79. King DE, Carek P, Mainous AG, et al. Inflammatory markers and exercise: differences related to exercise type. Medicine and Science in Sports and Exercise. 2003;35:575–581
  80. Wannamethee SG, Lowe GD, Whincup PH, et al. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation. 2002;105:1785–1790
  81. Abramson JL, Vaccarino V. Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Archives of Internal Medicine. 2002;162:1286–1292
  82. Geffken DF, Cushman M, Burke GL, et al. Association between physical activity and markers of inflammation in a healthy elderly population. American Journal of Epidemiology. 2001;153:242–250
  83. Smith JK, Dykes R, Douglas JE, et al. Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. JAMA : The Journal of the American Medical Association. 1999;281:1722–1727
  84. Mattusch F, Dufaux B, Heine O, et al. Reduction of the plasma concentration of C-reactive protein following nine months of endurance training. International Journal of Sports Medicine. 2000;21:21–24
  85. Taaffe DR, Harris TB, Ferrucci L, et al. Cross-sectional and prospective relationships of interleukin-6 and C-reactive protein with physical performance in elderly persons: MacArthur studies of successful aging. The Journals of Gerontology. 2000;55:M709–M715
  86. Fallon KE, Fallon SK, Boston T. The acute phase response and exercise: court and field sports. British Journal of Sports Medicine. 2001;35:170–173
  87. Wendel H, deStanchina E, Fridman S, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 2004;428:332–337
  88. deGraffenried L, Friedrichs W, Fulcher L, et al. Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity. Annals of Oncology. 2003;14:1051–1056

PII: S1521-690X(08)00094-8

doi: 10.1016/j.beem.2008.08.009

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 4 , Pages 659-669 , August 2008

Article Tools

* Image Usage & Resolution